EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor cell membrane camouflaged liposomal pharmaceuticals for cascade catalysis‐driven redox modulation and synergistic ROS/RNS antitumor therapy

Guangrong Zheng, Tengfei Ke, Hongjin Wang, Hong Huang, Ying Zhang, Guanghai Fei, Chengde Liao, Haiyan Yang

VIEW · 2026-06 · 7 (3)

DOI: 10.1002/viw.20250198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift VIEW, online erschienen am 04.02.2026. Verfasst von Guangrong Zheng und 7 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The antioxidant defense system (ADS) within the tumor microenvironment restricts the efficacy of reactive oxygen species (ROS) based therapies by conferring intrinsic redox tolerance. To overcome this limitation, we develop a tumor cell membrane camouflaged liposomal nanoplatform (C‐MLip@LA) that modulates the ADS to enhance tumor‐targeted therapy through a synergistic reactive oxygen/nitrogen species (ROS/RNS) cascade. The system encapsulates L‐arginine (LA) as the core, anchors MnO 2 nanoparticles on the liposomal surface, and is cloaked with homologous tumor cell membranes, thereby enabling tumor‐specific recognition and immune evasion. C‐MLip@LA disassembles after cellular internalization, where MnO 2 depletes intracellular glutathione (GSH) and is reduced to Mn 2 + , thereby elevating ROS levels and enabling T 1 ‐weighted magnetic resonance imaging. Concurrently, the released LA reacts with endogenous H 2 O 2 to generate nitric oxide (NO). The interplay between NO and ROS initiates a cascade reaction that produces highly cytotoxic peroxynitrite, thereby amplifying immunogenic cell death and leading to pronounced tumor growth inhibition in a CT‐2A tumor model. Collectively, this work presents a biomimetic nanoplatform for redox‐modulated cancer therapy with integrated diagnostic and immunomodulatory functions.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Zheng, G., Ke, T., Wang, H., Huang, H., Zhang, Y., Fei, G., Liao, C., & Yang, H. (2026). Tumor cell membrane camouflaged liposomal pharmaceuticals for cascade catalysis‐driven redox modulation and synergistic ROS/RNS antitumor therapy. VIEW, 7(3). https://doi.org/10.1002/viw.20250198

Vancouver

Zheng G, Ke T, Wang H, Huang H, Zhang Y, Fei G, et al. Tumor cell membrane camouflaged liposomal pharmaceuticals for cascade catalysis‐driven redox modulation and synergistic ROS/RNS antitumor therapy. VIEW. 2026;7(3). doi:10.1002/viw.20250198

BibTeX
@article{Zheng2026,
  author = {Zheng, Guangrong and Ke, Tengfei and Wang, Hongjin and Huang, Hong and Zhang, Ying and Fei, Guanghai and Liao, Chengde and Yang, Haiyan},
  title = {Tumor cell membrane camouflaged liposomal pharmaceuticals for cascade catalysis‐driven redox modulation and synergistic ROS/RNS antitumor therapy},
  journal = {VIEW},
  year = {2026},
  volume = {7},
  number = {3},
  doi = {10.1002/viw.20250198}
}
Kostenlos starten →